facebook pixel Skip to main content
Instructor:  James Greenblatt, MD
Date & Time: December 3 at 7:30 pm ET / 4:30 pm PT
Enrollment Fee: FREE 

What if a biological factor contributing to your patient’s persistent psychiatric symptoms could now be investigated with a new laboratory test?

For clinicians treating patients with ADHD, autism, anxiety, mood disorders, and challenging behaviors, understanding why symptoms persist is often the greatest challenge. While medications and therapies remain essential, they may not address every underlying biological contributor.

For decades, researchers have explored the potential influence of food-derived neuroactive peptides on brain function. Two of particular interest are casomorphin and gliadorphin, opioid-like peptides produced during the digestion of dairy and gluten. Yet evaluating these compounds has not been part of routine psychiatric practice.

Now, a breakthrough in testing is bringing new attention to this important area of nutritional psychiatry.

Register Now for FREE

With the reintroduction of specialized casomorphin and gliadorphin testing through DHA Laboratories, clinicians have a new opportunity to investigate these peptides and better understand individual differences in dietary protein metabolism.

Why should this matter to your practice?

Because patients with the same diagnosis may have very different biological contributors to their symptoms. This testing offers another avenue of investigation when patients aren’t responding as expected, while research continues to establish how test findings should inform clinical decisions.

Join Dr. James Greenblatt as he explores the science behind these neuroactive peptides, the relationship between gastrointestinal function and brain health, and how emerging laboratory testing may help clinicians ask more targeted questions about their patients’ individual biology.

What You’ll Learn

  • Understand the testing breakthrough: Discover what the newly available casomorphin and gliadorphin tests measure and their potential clinical applications.
  • Recognize a potentially overlooked biological pathway: Explore how food-derived neuroactive peptides may influence brain function and behavior.
  • Think differently about complex patients: Examine the possible relevance of these peptides in ADHD, autism, anxiety, mood disorders, and behavioral dysregulation.
  • Understand why patients respond differently: Learn how digestive enzymes, DPP-IV activity, intestinal permeability, and biochemical individuality may influence peptide metabolism.
  • Expand your clinical investigative approach: Consider how emerging testing may complement conventional psychiatric care and where further clinical validation is needed.

New Testing. New Questions. New Possibilities for Patient Care.

The more we understand about individual biology, the more precisely we can investigate the factors that may contribute to psychiatric symptoms. Join Dr. Greenblatt to learn about this emerging testing opportunity and what it could mean for your clinical practice.

Join Us & Register for FREE

PLEASE NOTE: All registrants will receive a link to watch the webinar recording post-event. Email reminders and replays are undeliverable to general or unmonitored emails (such as support@, info@ or admin@). The use of AI-powered note-taking tools, transcription services, or recording applications during live sessions is not permitted and Zoom may remove individuals from attendance if using these tools. This webinar recording will be available free for live attendees; attendees will be sent the recording link post-event. This webinar will remain free for the general public for two weeks post-webinar. After that point, the price increases to $19.

James Greenblatt MD

James Greenblatt, MD

A trailblazer in the field of functional and integrative psychiatry, James M. Greenblatt, MD, has treated thousands of patients since 1988. With over three decades of clinical experience, he is considered the leading authority on low-dose lithium for mental health, having pioneered its safe, evidence-based use in treating addiction, mood disorders, and cognitive decline. He is the author of ten books, including his newest, Finally Hopeful and The Lithium Revolution, and the bestseller, Finally Focused.

After receiving his medical degree and completing his psychiatry residency, Dr. Greenblatt completed a fellowship in Child and Adolescent Psychiatry at Johns Hopkins Medical School. For nearly 20 years he served as the Chief Medical Officer at Walden Behavioral Care in Waltham, MA, and currently as an Assistant Clinical Professor of Psychiatry at Tufts University School of Medicine and Dartmouth College Geisel School of Medicine. Dr. Greenblatt lectures internationally on the scientific evidence for functional and nutritional interventions for and mental illness. He is the Founder & Chief Medical Officer of Psychiatry Redefined, the leading continuing education platform for mental health providers.

Subscribe & Save 20%
on Your Next Course